3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Terminated
1
Completed
1
Sponsor Class
INDUSTRY
2
Study Type
Observational
1
Interventional
1
Sponsor
Cancer Type
Thoracic
7
Endocrine
6
Genitourinary
5
Gastrointestinal
3
Sarcoma
2
NET
2
Head & Neck
2
Dermatologic
2
CNS
2
Other solid neoplasm
1
Gynecologic
1
Breast
1
Conditions
Melanoma
783
Carcinoma, Non-Small-Cell Lung
170
Skin Neoplasms
154
Neoplasms
106
Neoplasm Metastasis
100
Colorectal Neoplasms
97
Carcinoma, Renal Cell
95
Uveal Melanoma
92
Breast Neoplasms
88
Squamous Cell Carcinoma of Head and Neck
85
Carcinoma, Basal Cell
83
Lung Neoplasms
81
Ovarian Neoplasms
79
Sarcoma
67
Lymphoma, T-Cell, Cutaneous
66
Carcinoma, Merkel Cell
66
Stomach Neoplasms
58
Pancreatic Neoplasms
58
Head and Neck Neoplasms
55
Carcinoma, Hepatocellular
53
Uterine Cervical Neoplasms
52
Urinary Bladder Neoplasms
50
Esophageal Neoplasms
44
Prostatic Neoplasms
43
Triple Negative Breast Neoplasms
42
Endometrial Neoplasms
41
Carcinoma, Squamous Cell
39
Brain Neoplasms
39
Carcinoma, Transitional Cell
37
Lymphoma
35
Interventions
enzalutamide
1
abiraterone
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
2 trials
Recent
Start date
Enrollment
Carcinoma, Small Cell
×
Dermatologic
×
1 year
×
Clear all
NCT05461430
2026-04-13
TraveraRTGx
Travera Inc
Completed
72 enrolled
NCT05551117
2026-02-09
Tamarack
MacroGenics
Phase 2
Terminated
192 enrolled
20 charts